New combo shows promise in Tough-to-Treat breast cancer

NCT ID NCT03414684

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin) helps people with metastatic triple-negative breast cancer live longer without their disease getting worse. About 78 participants with advanced cancer that has spread will receive either carboplatin alone or carboplatin plus nivolumab. The goal is to see if the combination improves progression-free survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center

Milford, Massachusetts, 01757, United States
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
Dana-Farber/New Hampshire Oncology-Hematology

Londonderry, New Hampshire, 03053, United States
Eastern Maine Medical Center

Bangor, Maine, 04401, United States
Ohio State University

Columbus, Ohio, 43210, United States
St. Elizabeth's Medical Center

Boston, Massachusetts, 02135, United States
The Stamford Hospital

Stamford, Connecticut, 06904, United States
University of Vermont Medical Center

Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.